

1 Results of a nationally representative seroprevalence survey of 2 chikungunya virus in Bangladesh

3

4 Sam W. Allen¹, Gabriel Ribeiro Dos Santos¹, Kishor K Paul^{2,3,4}, Repon Paul^{4,5}, Ziaur Rahman⁴,
5 Mohammad Shafiul Alam⁴, Mahmudur Rahman⁶, Hasan Mohammad Al-Amin^{4,7,8}, Jessica
6 Vanhomwegen¹⁰, Taylor Smull¹¹, Kyu Han Lee¹², Emily S. Gurley^{11*}, Henrik Salje^{1,11*}

7

8 1. Department of Genetics, University of Cambridge, Cambridge, UK

9 2. Kirby Institute, University of New South Wales, Sydney, Australia

10 3. School of Population Health, University of New South Wales, Sydney, Australia

11 4. icddr,b, Dhaka, Bangladesh

12 5. Centre for Big Data Research in Health, University of New South Wales, Sydney, Australia

13 6. IEDCR, Dhaka, Bangladesh

14 7. QIMR Berghofer Medical Research Institute, Queensland, Australia

15 8. School of the Environment, The University of Queensland, Queensland, Australia

16 10. Institut Pasteur, Paris, France

17 11. Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore,
18 USA

19 12. Emory Global Health Institute, Emory University, Atlanta, USA

20

21

22 * joint senior authors

23

24

25 Abstract

26

27 Chikungunya virus (CHIKV) is responsible for a rapidly increasing but poorly understood infection
28 burden globally. Bangladesh experienced its first reported outbreak in 2008. Despite a number of
29 subsequent isolated outbreaks, culminating in an enormous nationwide epidemic in 2017, very little is
30 known about the burden or dynamics of chikungunya within the country, and the risk factors for
31 infection. We conducted a nationally representative seroprevalence survey in 2016 in 70 randomly
32 selected communities across the country. Individuals provided blood samples, which were tested for
33 the presence of IgG antibodies to CHIKV. We also trapped and speciated mosquitoes. We found that
34 69/2,938 (2.4%) of individuals were seropositive to CHIKV. Seropositive individuals were
35 concentrated in the centre and south of the country. We found that being seropositive to dengue virus
36 (aOR 3.11 [95% CIs: 1.17 – 24.45]) and male sex (aOR 0.29 [95% CIs: 0.01 – 0.96]), were significantly
37 associated with CHIKV seropositivity, however, *Aedes* presence, income, and travel history were not.
38 Using a spatial prediction model, we estimate that at the time of the study, 4.99 million people in the
39 country had been infected with CHIKV. These findings highlight high population susceptibility prior
40 to the major outbreak in 2017 and that historic outbreaks must have been spatially isolated.

41

42

43 **Keywords:** chikungunya; seroprevalence, Bangladesh

44

45

46

47

48

49

50

51 Introduction

52

53 Chikungunya virus (CHIKV) is an *Aedes-transmitted* arbovirus first detected in Tanzania in 1953 which
54 has since spread to the rest of Africa, Asia and South America, as well as sporadic outbreaks elsewhere
55 [1]. The hallmark symptoms of chikungunya are abrupt onset of fever and joint pain [2,3], commonly
56 accompanied by a rash [4]. The clinical presentation of chikungunya in humans is similar to that of
57 dengue and a range of other illnesses, so is often misdiagnosed [2,5–9]. Around half of infected
58 individuals suffer long-term effects, the most common of which is arthralgia [10–15] that can continue
59 for months or even years post-infection, severely decreasing quality of life [16–18]. High attack rates
60 coupled with frequent severe, persistent symptoms means that CHIKV outbreaks can place a large
61 burden on communities, especially in lower-middle-income countries [2].

62

63 Limited access to testing and misdiagnoses mean that entire CHIKV epidemics are frequently missed,
64 especially in lower-middle-income countries [19,20] and we rarely have a good understanding of the
65 underlying burden from CHIKV in any affected setting, as well as individual-, household- and
66 population-level predictors of infection risk. This critical knowledge gap means we do not know where
67 to appropriately target interventions. This is becoming increasingly relevant, with the licensure of the
68 first chikungunya vaccines expected in the near future and the demonstration that the targeted release
69 of *Wolbachia*-infected mosquitoes can reduce incidence [21,22]. In this context, seroprevalence studies
70 can help, especially as CHIKV infection appears to result in long-lasting and immunising
71 antibodies[23]. By measuring the presence of antibodies in the population, we can quantify the
72 underlying level of infection history in a population[20]. Further, by combining the results of
73 seroprevalence studies from multiple locations with mathematical models, we can estimate the burden
74 across the population, and the changing level of immunity [24].

75

76 Here we focus on Bangladesh. CHIKV was first identified in Bangladesh in 2008 during an outbreak
77 in the northwest of the country in two villages near the Indian border [25]. Subsequently, there were
78 localised outbreaks detected between 2011 and 2016 [2,26]. In 2017, Bangladesh experienced a far
79 larger outbreak, with infections reported nationwide with as many as a million reported cases in total
80 [2,27,28]. However, it remains unclear if there was substantial transmission across the country prior to
81 the large outbreak in 2017. In this project, we present the results of a nationally representative
82 seroprevalence study from Bangladesh. We visited communities around the country in 2016, allowing
83 us to quantify the level of transmission, identify risk factors for infection, and the level of immunity
84 prior to the major outbreak.

85

86

87

88 Results

89

90 We visited 70 randomly selected communities in Bangladesh. We collected blood and administered
91 questionnaires from 2,938 individuals. Simultaneously, we collected mosquitoes using BG-Sentinel
92 traps during our survey. There was a mean of 42 participating individuals per community (range 39-
93 57), and a mean of 10 participating households per community (range 10-12). The mean age of
94 participants was 30 and 52% of participants were female. Our IgG Luminex-based antibody assay
95 divided individuals into seropositive and seronegative individuals (Figure S1). Among the participants,
96 2.4% were seropositive to CHIKV, with all seropositive individuals coming from 16 communities (23%
97 of all communities), concentrated in the central and south of the country. Among seropositive
98 communities, mean seropositivity was 10.45%, ranging from 2.08 to 39.02%. Notably, a single
99 individual from the 3 communities in Dhaka city were seropositive. Seropositivity was largely
100 consistent across different age groups, except for those aged under five years in age, who had a
101 seropositivity of 0% compared to 2.4% for those over five years (p-value 0.26) (Table 1). We used
102 logistic regression to identify covariates associated with being seropositive. We compared models with
103 or without a spatial covariance term, as well as models with or without household and community level
104 random intercepts. The best fitting model, as measured by WAIC (Watanabe-Akaike information
105 criterion, a measure for model comparison), included household and community level random

106 intercepts, however, covariate estimates were largely consistent across the different models considered
107 (Figure S2).

108

109 We compared a suite of models to identify individual-, household- and community- level covariates
110 linked to CHIKV seropositivity. These models either included or did not include household and
111 community random effects and a spatial field. The best fitting model had both household and
112 community random effects but no spatial field (Table S1). In this model, we found most factors were
113 not associated with CHIKV seropositivity. This includes the presence of *Aedes aegypti* and *Ae.*
114 *albopictus* in the community, population density, household income and travel history. However, being
115 aged under 5 years (aOR: 0.00, 95% CI: 0.00 – 0.0003), being seropositive for dengue virus (aOR: 3.11,
116 95% CI: 1.17 – 24.45), male sex (aOR: 0.29, 95% CI: 0.01 – 0.96) and household ownership (aOR:
117 0.06, 95% CI: 0.00 – 0.81) were significantly associated. Either *Ae. aegypti* or *Ae. albopictus* was found
118 in 46 communities (66% of communities) (Figure S3).

119

120 We next explored whether within the communities where CHIKV seropositivity was detected, living
121 with a seropositive individual was a risk factor for being seropositive. We found that within these
122 communities, individuals who lived with a seropositive householder member had 2.80 (95% CIs: 1.47
123 – 4.85) times the probability of being seropositive as compared to individuals living with only
124 seronegative individuals.

125

126 To estimate the overall seropositivity across the country, we used a spatial prediction model. We used
127 the estimated population distribution in the country to identify the number of infected individuals.
128 Overall, we estimate that 4.99 million people (95% CI: 4.89 - 5.08 million) in Bangladesh had been
129 infected with chikungunya at some point in their lives as of 2016, with the highest risk concentrated to
130 a few focal hotspots (Figure 2A). This equates to about 2.49% (95% CI: 2.45 – 2.54%) of the national
131 population, consistent with the estimate produced using the crude proportion seropositive among
132 individuals in the serosurvey (2.35% of the population, or about 4.70 million individuals). To validate
133 our spatial prediction model, we removed all data from a subset of individual communities in turn from
134 our model and used the remaining data to fit a new model. We then used the fitted model to predict in
135 the removed locations. We found we could accurately predict seropositivity in the removed locations
136 (Pearson correlation of 0.95) (Figure 2B).

137

138

139 Discussion

140

141 The results from this first nationally-representative serosurvey of CHIKV infection in Bangladesh
142 demonstrate that by 2016, CHIKV had been present in parts of the country, especially the South.
143 Overall, only a relatively small proportion of the population, representing around 5 million individuals,
144 had previously been infected. The high level of population susceptibility at this time can help explain
145 the magnitude and spatial extent of the subsequent major outbreak in 2017.

146

147 CHIKV seropositivity was relatively constant across age groups, which indicates that individuals of all
148 ages have had the same cumulative exposure to risk of infection. This is indicative of a recent emergence
149 of CHIKV in Bangladesh, though the decreased seropositivity among those aged under five suggests
150 limited exposure in the years immediately preceding the serosurvey. We explored a wide range of
151 individual-, household- and community- level risk factors to identify drivers of infection risk. Being
152 seropositive to dengue virus, another virus transmitted by the same vectors, was an important predictor.
153 This highlights the overlapping risk across *Aedes*-transmitted arboviruses, as previously identified
154 elsewhere [29]. We identified a strong effect of the household, with individuals much more likely to be
155 seropositive if they lived with other seropositive individuals. This finding is consistent with previous
156 findings from Bangladesh and elsewhere that have identified the limited flight range of the vector as
157 driving household infection risk, as biting typically occurs in the peridomestic environment [30]. A
158 strong correlation of serostatus by household has also been observed with dengue virus [31]. Sex was
159 another notable predictor, consistent with results from both Bangladesh and elsewhere that have
160 consistently shown infection risk is higher among females [19,30,32–34]. It has been suggested that

161 differences in mobility patterns may explain this increased risk, with women in Bangladesh spending
162 more time in and around the home where mosquitoes reside [30].

163

164 Our results suggest that while prior to 2017 CHIKV outbreaks in Bangladesh have been spatially
165 constrained, there was always the risk of a widespread epidemic. It remains unclear why prior outbreaks
166 in the country died out without spreading widely. We identified either *Ae. aegypti* or *Ae. albopictus*
167 mosquitoes in most communities, suggesting that conditions were suitable for transmission across the
168 country. Introductions may have previously been in rural communities, which are less connected to
169 urban hubs, and potentially died out from entering cooler parts of the year [30]. As population mobility
170 continues to increase, we can expect even wider spread of both *Aedes* vectors and a concurrent increase
171 in arbovirus outbreak risk [35].

172

173 This project highlights the utility of nationally representative seroprevalence studies, especially when
174 combined with mathematical models. Using a sampling frame of all communities in Bangladesh allows
175 us to generalise to the wider country. These same samples were used to create risk maps for a wide
176 range of other pathogens, including cholera, dengue, and hepatitis E [24,36,37]. Further, the increased
177 use of multiplex serology allows the parallel testing of multiple pathogens, maximising insights from
178 individual blood draws, and limiting the need for numerous freeze-thaw cycles.

179

180 We note that our modelled estimate of seropositivity at the national level was very consistent with the
181 crude level of seropositivity in our sample set (2.49% vs 2.35%). It is certainly possible that we did not
182 sample communities affected by localised outbreaks but those outbreaks would not markedly change
183 our estimates for the overall population level immunity for Bangladesh. Selection bias may have arisen
184 in that individuals who were away from communities during visits, and hence more likely to travel
185 frequently, may not have been able to participate. However, to minimise this risk, the study team
186 arranged to visit households again when members were expected to return from travel. The travel
187 covariate is also limited in that the questionnaire asked about most recent travel outside the community,
188 which does not provide information on frequency, reason or destination of travel. All of these could be
189 relevant to CHIKV infection risk.

190

191 In conclusion, we demonstrate high CHIKV susceptibility across Bangladesh prior to the major
192 outbreak in 2017, and that prior outbreaks were largely spatially isolated in nature. Given the potential
193 for large outbreaks, Bangladesh should be prioritised for new interventions, such as vaccines and
194 *Wolbachia*-based vector control, as they become available.

195

196

197

198

199

200

201

202

203

204

205

206

207 **Methods**

208

209 *Data collection*

210

211 The protocol of the study has been described elsewhere [24]. Briefly, to obtain a nationally-
212 representative sample, 70 of the 97,162 communities listed in the 2011 census were selected at random,
213 with the likelihood of selection being proportional to population size. Each community was visited by
214 the study team, who spent at least five days within each community. Visits occurred during October
215 2015 to January 2016. A further visit was made to communities where no *Aedes* had been previously
216 trapped, during June and July 2016 for additional mosquito collection. Communities where *Aedes* were
217 still not found after the second visit were defined as having an absence of *A. aegypti* and *A. albopictus*.
218 The study team randomly selected at least ten households from each community. The heads of selected
219 households were informed of the study and invited to participate. If they agreed, all other members of
220 the household aged over six months were also invited to participate. Data collection was deemed to be
221 complete for a community when at least 40 serum samples from at least 10 households were obtained.
222

223 The head of each participating household was led through a household questionnaire with a variety of
224 questions regarding socio-economic status, such as education level, estimated household income and
225 access to electricity. In addition, this questionnaire asked whether households had used any form of
226 mosquito control in the last week and whether any member of the household owned land away from
227 their home [33].
228

229 Each consenting household member (including the household head) was also guided through an
230 individual-level questionnaire. If individuals were too young to answer this by themselves, an older
231 household member was asked to answer on their behalf. These questionnaires covered demographic
232 questions, such as age and sex, and also asked when participants had last travelled outside of the
233 community [33].
234

235 All individuals who provided consent also had 5 ml of venous blood withdrawn by a phlebotomist.
236 These blood samples were centrifuged and serum was then extracted separately and shipped in nitrogen
237 dry shippers to icddr,b (International Centre for Diarrhoeal Disease Research, Bangladesh) laboratories
238 in Dhaka. Individuals who were ill at the time of the survey were excluded from serum sampling. All
239 serum samples were tested for antibodies against chikungunya to identify evidence of prior infection.
240 This was done using a microsphere-based multiplex immuno-assay (MMIA) that measured the
241 fluorescence intensity to both the recombinant E2 glycoprotein of the chikungunya virus and the
242 background level of antibody activity at the individual level using a recombinant human O⁶-
243 Methylguanine-DNA Methyltransferase protein (SNAP-tag) . To determine CHIKV seropositive we
244 first calculated the ratio between the fluorescence intensity to CHIKV and the control MGMT protein,
245 and used a cut point of 5.5 to identify those with a history of CHIKV exposure (Figure S1). It has
246 previously been estimated that a ratio of 5.5 on a linear scale (~1.70 log scale) is the threshold for the
247 MMIA to achieve 95% sensitivity and specificity (personal communication) [19].
248

249 *Regression analyses*

250

251 We used the R-INLA package, which applies the INLA (Integrated nested Laplace approximation)
252 method. INLA is a Bayesian approach to statistical inference for Gaussian Markov Random Field
253 (GMRF) models [38]. A key benefit of INLA is that it can accommodate a range of GMRF models,
254 including those with a spatial component. R-INLA allows these to be added to the model as random
255 effects. This means that the spatial autocorrelation inherent in epidemiological data can be accounted
256 for to isolate out the role of random spatial variation [39]. We modelled the dependence of two
257 observations in this distribution using a covariance function, with the Matérn covariance function. R-
258 INLA's default priors were used beyond the setting of the spatial field, where a fixed smoothness
259 parameter of $\nu = 2$ was set. This represents a moderately smooth spatial field, and is a commonly selected
260 value [40].
261

262 Covariates were divided into individual-level (age, sex, dengue serostatus and last time left
263 community), household-level (income, highest education level achieved by head of household,
264 electricity in home, own home, own land away from the home and use of mosquito control in the last
265 week) and community level (*Ae. aegypti* captured in the community, *Ae. albopictus* captured in the
266 community, division and log population density). Firstly, each covariate was included in a univariate
267 logistic regression using R-INLA to assess individual relationships with serostatus. Random intercepts
268 were also included for both the household and the community to account for correlation of observations
269 within these sites. Following this, all covariates were included in a multivariable analysis. This
270 generated an odds ratio and 95% confidence interval for each covariate from both univariate regression,
271 and an adjusted odds ratio and 95% confidence interval from multivariable regression.

272
273 To explore the importance of the spatial correlation structure and the random household and community
274 intercepts, additional models with different combinations of these included were also built. In total, five
275 models were created:

- 276 1. The base model, featuring a Matérn spatial correlation structure, a random community intercept
277 and a random household intercept.
- 278 2. A Matérn spatial correlation structure and a random household intercept only.
- 279 3. A Matérn spatial correlation structure and a random community intercept only.
- 280 4. A Matérn spatial correlation structure only.
- 281 5. Random household and community intercepts only.

282
283 Using the base model, the percentage of variance explained by each spatial correlation structure, random
284 community intercept and random household intercept was determined. A model without any of these
285 three was first run, and the variance calculated by taking the mean of the squared residuals. The three
286 random effects were then added one-by-one. Each time, the variance was calculated and the percentage
287 of the variance in the original model that the new model explained was estimated, to try and understand
288 the impact of each addition. This was repeated both by adding the random community intercept before
289 the random household intercept, and vice-versa.

290
291
292 *Household infection risk*

293
294 To investigate whether living with a seropositive individual was a risk factor for being seropositive
295 oneself, the risk ratio for living with a seropositive individual was calculated in the subset of
296 communities with at least one seropositive individual. The risk ratio was then calculated as follows:

$$297 \text{Risk Ratio} = \frac{a}{b}$$

298 where,
299 a = the proportion of seropositive individuals living with seropositive individuals
300 b = the proportion of seropositive individuals living with seronegative individuals

301
302
303 This risk ratio was first calculated, and then bootstrapped for 1000 iterations to generate a distribution
304 of estimates, from which a mean and 95% confidence intervals were extracted.

305
306
307 *Mapping chikungunya virus risk across Bangladesh*

308
309 Seroprevalence by community was mapped by community to visualise the general spatial distribution
310 of chikungunya in 2015/2016. Seroprevalence was defined as the number of individuals with detectable
311 anti-chikungunya virus antibodies, expressed as a proportion of the total number of individuals
312 surveyed in that community, calculated as follows:

$$313 \text{seroprevalence} = \frac{\text{number of seropositive individuals}}{\text{total population}}$$

314

315
316 95% confidence intervals were also calculated for community seroprevalence using the Clopper-
317 Pearson estimation method which is based on the exact binomial distribution (66). Seroprevalence was
318 calculated for each community in the study and mapped to visualise spatial trends.

319
320 To explore infection risk across Bangladesh, a grid of 1 km x 1 km cells was placed over the country.
321 A Bayesian framework featuring a Matérn spatial correlation structure was used to fit the model.
322 Covariates from the multivariable regression could not be added to the spatial prediction because values
323 for these covariates are not available for areas outside the study sites. Salje et al. [24] found that the
324 inclusion of additional covariates (e.g. age and sex) beyond the spatial covariance term that can be
325 obtained from demographic data did not markedly improve predictive accuracy, so these were not added
326 to reduce unnecessary model complexity. The model was then fit to the 1 km x 1 km grid across the
327 country to predict the seroprevalence in each of these cells.

328
329 To estimate the total number of people ever infected with CHIKV in Bangladesh at the time of the
330 survey, the population density in each cell was multiplied by the fitted seroprevalence in each cell.
331 Confidence intervals were generated by taking the 0.025 and 0.975 estimates from the model and
332 applying the same technique.

333
334 To test the predictive performance model, a cross validation was performed. 1000 iterations were
335 performed, with ten of the 70 communities left out during model fitting each run. The model was then
336 used to predict the seroprevalence in the ten test communities. The mean predicted seroprevalence for
337 each community was then used to generate an estimated seroprevalence, which was compared to the
338 observed seroprevalence in each of the held out communities.

339
340
341 *Ethical clearance*

342
343 The icddr,b and CDC ethical review boards approved of this study (protocol number PR-14058). All
344 participating adults gave written informed consent. Children involved in the study had written, informed
345 consent provided on their behalf by parents/guardians.

346

347 References

- 348 1. Zeller H, Van Bortel W, Sudre B. Chikungunya: Its History in Africa and Asia and Its Spread to
349 New Regions in 2013–2014. *J Infect Dis.* **2016**; 214(suppl 5):S436–S440.
- 350 2. Anwar S, Taslem Mourosi J, Khan MF, Ullah MO, Vanakker OM, Hosen MJ. Chikungunya
351 outbreak in Bangladesh (2017): Clinical and hematological findings. *PLoS Negl Trop Dis.* **2020**;
352 14(2):e0007466.
- 353 3. Suhrbier A, Jaffar-Bandjee M-C, Gasque P. Arthritogenic alphaviruses--an overview. *Nat Rev*
354 *Rheumatol.* **2012**; 8(7):420–429.
- 355 4. Nsoesie EO, Kraemer MU, Golding N, et al. Global distribution and environmental suitability
356 for chikungunya virus, 1952 to 2015. *Euro Surveill [Internet].* **2016**; 21(20). Available from:
357 <http://dx.doi.org/10.2807/1560-7917.ES.2016.21.20.30234>
- 358 5. Girard M, Nelson CB, Picot V, Gubler DJ. Arboviruses: A global public health threat. *Vaccine.*
359 **2020**; 38(24):3989–3994.
- 360 6. Morrison TE. Reemergence of chikungunya virus. *J Virol.* **2014**; 88(20):11644–11647.
- 361 7. Reller ME, Akoroda U, Nagahawatte A, et al. Chikungunya as a cause of acute febrile illness in
362 southern Sri Lanka. *PLoS One.* **2013**; 8(12):e82259.
- 363 8. Sy AK, Chan V, Bautista A, Capeding MR. Prevalence of chikungunya virus infection among
364 suspected dengue pediatric patients in 3 regional hospitals in the Philippines. *Int J Infect Dis.*
365 **2012**; 16:e112.
- 366 9. Hossain MS, Hasan MM, Islam MS, et al. Chikungunya outbreak (2017) in Bangladesh: Clinical
367 profile, economic impact and quality of life during the acute phase of the disease. *PLoS Negl*
368 *Trop Dis.* **2018**; 12(6):e0006561.
- 369 10. Puntasecca CJ, King CH, LaBeaud AD. Measuring the global burden of chikungunya and Zika
370 viruses: A systematic review. *PLoS Negl Trop Dis.* **2021**; 15(3):e0009055.
- 371 11. Rodríguez-Morales AJ, Calvache-Benavides CE, Giraldo-Gómez J, et al. Post-chikungunya
372 chronic arthralgia: Results from a retrospective follow-up study of 131 cases in Tolima,
373 Colombia. *Travel Med Infect Dis.* **2016**; 14(1):58–59.
- 374 12. Rodríguez-Morales AJ, Restrepo-Posada VM, Acevedo-Escalante N, et al. Impaired quality of
375 life after chikungunya virus infection: a 12-month follow-up study of its chronic inflammatory
376 rheumatism in La Virginia, Risaralda, Colombia. *Rheumatol Int.* **2017**; 37(10):1757–1758.
- 377 13. Kirkland K, Brantley JK, Handey GM. Family medicine education in Alabama. *Ala Med.* **1989**;
378 59(6):26, 28–9.
- 379 14. Tritsch SR, Encinales L, Pacheco N, et al. Chronic Joint Pain 3 Years after Chikungunya Virus
380 Infection Largely Characterized by Relapsing-remitting Symptoms. *J Rheumatol.* **2020**;
381 47(8):1267–1274.
- 382 15. Genderen FT van, Krishnadath I, Sno R, Grunberg MG, Zijlmans W, Adhin MR. First
383 Chikungunya Outbreak in Suriname; Clinical and Epidemiological Features. *PLoS Negl Trop*
384 *Dis.* **2016**; 10(4):e0004625.
- 385 16. Moro ML, Grilli E, Corvetta A, et al. Long-term chikungunya infection clinical manifestations
386 after an outbreak in Italy: a prognostic cohort study. *J Infect.* **2012**; 65(2):165–172.

- 387 17. Couturier E, Guillemin F, Mura M, et al. Impaired quality of life after chikungunya virus
388 infection: a 2-year follow-up study. *Rheumatology* . **2012**; 51(7):1315–1322.
- 389 18. O’Driscoll M, Salje H, Chang AY, Watson H. Arthralgia resolution rate following chikungunya
390 virus infection. *Int J Infect Dis*. **2021**; 112:1–7.
- 391 19. Lim JK, Ridde V, Agnandji ST, et al. Seroepidemiological Reconstruction of Long-term
392 Chikungunya Virus Circulation in Burkina Faso and Gabon. *J Infect Dis*. **2023**; 227(2):261–267.
- 393 20. Salje H, Cauchemez S, Alera MT, et al. Reconstruction of 60 Years of Chikungunya
394 Epidemiology in the Philippines Demonstrates Episodic and Focal Transmission. *J Infect Dis*.
395 **2016**; 213(4):604–610.
- 396 21. Schneider M, Narciso-Abraham M, Hadl S, et al. Safety and immunogenicity of a single-shot
397 live-attenuated chikungunya vaccine: a double-blind, multicentre, randomised, placebo-
398 controlled, phase 3 trial. *Lancet*. **2023**; 401(10394):2138–2147.
- 399 22. Ribeiro dos Santos G, Durovni B, Saraceni V, et al. Estimating the effect of the wMel release
400 programme on the incidence of dengue and chikungunya in Rio de Janeiro, Brazil: a
401 spatiotemporal modelling study. *Lancet Infect Dis*. **2022**; 22(11):1587–1595.
- 402 23. Yoon I-K, Srikiatkachorn A, Alera MT, Fernandez S, Cummings DAT, Salje H. Pre-existing
403 chikungunya virus neutralizing antibodies correlate with risk of symptomatic infection and
404 subclinical seroconversion in a Philippine cohort. *Int J Infect Dis*. **2020**; 95:167–173.
- 405 24. Salje H, Paul KK, Paul R, et al. Nationally-representative serostudy of dengue in Bangladesh
406 allows generalizable disease burden estimates. *Elife* [Internet]. **2019**; 8. Available from:
407 <http://dx.doi.org/10.7554/eLife.42869>
- 408 25. Khatun S, Chakraborty A, Rahman M, et al. An Outbreak of Chikungunya in Rural Bangladesh,
409 2011. *PLoS Negl Trop Dis*. **2015**; 9(7):e0003907.
- 410 26. Wahid B, Ali A, Rafique S, Idrees M. Global expansion of chikungunya virus: mapping the 64-
411 year history. *Int J Infect Dis*. **2017**; 58:69–76.
- 412 27. Kabir I, Dhimal M, Müller R, Banik S, Haque U. The 2017 Dhaka chikungunya outbreak. *Lancet*
413 *Infect Dis*. **2017**; 17(11):1118.
- 414 28. Islam MT, Atiqul Haque M, Anjum A, et al. Seroprevalence of Chikungunya Virus Infection in
415 an Urban Slum Population of Bangladesh: A Cross-Sectional Study. *J Curr Adv Med Res*. **2022**;
416 9(1):3–8.
- 417 29. Rodríguez-Barraquer I, Solomon SS, Kuganatham P, et al. The Hidden Burden of Dengue and
418 Chikungunya in Chennai, India. *PLoS Negl Trop Dis*. **2015**; 9(7):e0003906.
- 419 30. Salje H, Lessler J, Paul KK, et al. How social structures, space, and behaviors shape the spread
420 of infectious diseases using chikungunya as a case study. *Proc Natl Acad Sci U S A*. **2016**;
421 113(47):13420–13425.
- 422 31. Santos GR dos, Santos GR dos, Buddhari D, et al. Individual, Household, and Community
423 Drivers of Dengue Virus Infection Risk in Kamphaeng Phet Province, Thailand [Internet]. *The*
424 *Journal of Infectious Diseases*. 2022. p. 1348–1356. Available from:
425 <http://dx.doi.org/10.1093/infdis/jiac177>
- 426 32. Mdho R, Patwary MH, Imtiaz A, et al. Seroprevalence of Chikungunya during Outbreak in
427 Dhaka, Bangladesh in 2017. *Journal of Virology & Antiviral Research* [Internet]. *SciTechnol*;
428 **2018** [cited 2023 Nov 3]; 2018. Available from: <https://www.scitechnol.com/peer->

- 429 review/seroprevalence-of-chikungunya-during-outbreak-in-dhaka-bangladesh-in-2017-
430 UNsR.php?article_id=8265
- 431 33. Shourav AH, Murshida Mahbub M, Yasmin M, Ahsan CR, Nessa J. Seroepidemiology of
432 Chikungunya Fever in Dhaka, Bangladesh: A Crosssectional Study. *Banglad J Microbiol.* **2021**;
433 38(2):79–85.
- 434 34. Hozé N, Salje H, Rousset D, et al. Reconstructing Mayaro virus circulation in French Guiana
435 shows frequent spillovers. *Nat Commun.* **2020**; 11(1):2842.
- 436 35. Mahmud AS, Kabir MI, Engø-Monsen K, et al. Megacities as drivers of national outbreaks: The
437 2017 chikungunya outbreak in Dhaka, Bangladesh. *PLoS Negl Trop Dis.* **2021**; 15(2):e0009106.
- 438 36. Azman AS, Lauer SA, Bhuiyan TR, et al. *Vibrio cholerae* O1 transmission in Bangladesh:
439 insights from a nationally representative serosurvey. *Lancet Microbe.* **2020**; 1(8):e336–e343.
- 440 37. Azman A, Paul KK, Bhuiyan TR, et al. Hepatitis E in Bangladesh: Insights from a National
441 Serosurvey. medRxiv [Internet]. Cold Spring Harbor Laboratory Press; **2021**; . Available from:
442 <https://www.medrxiv.org/content/10.1101/2021.06.14.21258872v1.abstract>
- 443 38. Rue H, Held L. Gaussian Markov random fields: Theory and applications [Internet]. London,
444 England: Chapman and Hall; 2004. Available from:
445 [https://www.taylorfrancis.com/books/mono/10.1201/9780203492024/gaussian-markov-random-](https://www.taylorfrancis.com/books/mono/10.1201/9780203492024/gaussian-markov-random-fields-havard-rue-leonhard-held)
446 [fields-havard-rue-leonhard-held](https://www.taylorfrancis.com/books/mono/10.1201/9780203492024/gaussian-markov-random-fields-havard-rue-leonhard-held)
- 447 39. Gomez-Rubio V. Bayesian inference with INLA. CRC Press; 2020.
- 448 40. Lindgren F, Rue H, Lindström J. An Explicit Link between Gaussian Fields and Gaussian
449 Markov Random Fields: The Stochastic Partial Differential Equation Approach. *J R Stat Soc*
450 *Series B Stat Methodol.* Oxford Academic; **2011**; 73(4):423–498.

451


452

453 **Footnotes**


454 The authors would like to acknowledge funding from ERC 804744 and the CDC. The authors declare
455 no conflicts of interest.

456

457 **Figure 1**




458



459

460 **Figure 1: Proportion seropositive. (A)** Map of sampled communities and proportion seropositive to
461 CHIKV. **(B)** Proportion seropositive by age.

462 **Figure 2**



463

464 **Figure 2: Estimated map of seropositivity.** (A) Modelled seropositivity in Bangladesh in 2016 (B)
465 Held out cross validation where communities were removed from model fitting process and the rest of
466 the data used to fit models. The plot shows the comparison with the observed versus the predicted in
467 the removed locations.

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483 **Table 1: Individual-, household- and community-level characteristics of participants across**
 484 **Bangladesh, stratified by serostatus to chikungunya in 2015/16.** Seropositivity determined based on
 485 the presence of IgG antibodies against CHIKV.

	N	Seropositive (N=69)	Seronegative (N=2,869)	p-value*
Individual level				
	n	n (%)	n (%)	
Age (years):				N/A
<5	88	0 (0%)	88 (100%)	
5-10	341	7 (2%)	334 (98%)	
11-20	737	16 (2%)	721 (98%)	
21-30	518	12 (2%)	506 (98%)	
31-40	417	8 (2%)	409 (98%)	
41-50	367	10 (3%)	357 (97%)	
51-60	242	11 (5%)	231 (95%)	
>60	228	5 (2%)	223 (98%)	
Sex:				0.087
Female	1,532	43 (3%)	1,489 (97%)	
Male	1,406	26 (2%)	1,380 (98%)	
Dengue Status:				<0.001
Seropositive	697	34 (5%)	663 (95%)	
Seronegative	2,237	35 (5%)	2,202 (98%)	
Unknown	4	0	4	
Last time left community:				0.8
≤180 days	1,704	41 (2%)	1,663 (98%)	
>180 days	1,234	28 (2%)	1,206 (98%)	
Household level				
Household income (Taka, 100 Taka = 0.9 USD):				0.8
<10,000	850	18 (2%)	832 (98%)	
10,000-20,000	1,107	26 (2%)	26 (2%)	
>20,000	969	25 (3%)	25 (3%)	
Unknown	12	0	12	
Household head education:				0.6
No Education	908	23 (3%)	885 (97%)	
Primary School	759	14 (2%)	745 (98%)	
High School	797	20 (3%)	777 (97%)	

Higher	401	12 (3%)	389 (97%)	
Unknown	73	0	73	
Electricity in home:				0.3
No	187	4 (1%)	269 (99%)	
Yes	2,751	65 (2%)	2,600 (98%)	
Own home:				0.2
No	187	7 (4%)	180 (96%)	
Yes	2,751	62 (2%)	2,689 (98%)	
Own land away from the home:				0.016
No	598	22 (4%)	576 (96%)	
Yes	2,340	47 (2%)	2,293 (98%)	
Mosquito control used:				0.3
No	1,067	21 (2%)	1,046 (98%)	
Yes	1,871	48 (3%)	1,823 (97%)	
Community level				
<i>Aedes aegypti</i> captured:				<0.001
No	1,973	33 (2%)	1,940 (98%)	
Yes	965	36 (4%)	929 (96%)	
<i>Aedes albopictus</i> captured:				0.5
No	1,707	43 (3%)	1,664 (97%)	
Yes	1,231	26 (2%)	1,205 (98%)	
Community type:				0.2
Rural	2,185	47 (2%)	2,138 (98%)	
Urban	753	22 (3%)	731 (97%)	
Division:				
Barisal	166	5 (3%)	161 (97%)	
Chittagong	779	18 (2%)	761 (98%)	
Dhaka	733	20 (3%)	713 (97%)	
Khulna	334	25 (7%)	309 (93%)	
Rajshahi	336	1 (1%)	335 (99%)	
Rangpur	462	0 (0%)	462 (100%)	
Sylhet	128	0 (0%)	128 (100%)	

*Pearson's Chi-squared test

486
487

488
489
490
491

Table 2: Results of univariate and multivariable logistic regression. The multivariable model selected included random community and household intercepts, but no spatial field (Model 5), on the basis of WAIC (Table S1).

	Univariate	Multivariable
Individual level	Odds ratio (95% confidence interval)	Adjusted odds ratio (95% confidence interval)
Age group (years):		
<5	0.00 (0.00 – 1.58)	0.00 (0.00 – 0.0003)
5-10	0.99 (0.37 – 2.65)	1.06 (0.38 – 3.04)
11-20	REF	REF
21-30	1.01 (0.44 – 2.32)	0.71 (0.21 – 1.85)
31-40	0.96 (0.38 – 2.43)	0.70 (0.20 – 2.04)
41-50	1.42 (0.58 – 3.46)	1.63 (0.55 – 7.48)
51-60	2.13 (0.87 – 5.23)	3.35 (0.83 – 118.52)
>60	0.91 (0.30 – 2.75)	0.82 (0.24 – 2.67)
Sex:		
Female	REF	REF
Male	0.66 (0.31 – 1.17)	0.29 (0.01 – 0.96)
Dengue Status:		
Seronegative	REF	REF
Seropositive	2.06 (1.14 – 3.84)	3.11 (1.17 – 24.45)
Last time left community:		
≤180 days	REF	REF
>180 days	0.90 (0.51 – 1.57)	0.59 (0.06 – 1.42)
Household level		
Household income (Taka):		
<10,000	REF	REF
10,000 – 20,000	0.74 (0.38 – 1.49)	0.68 (0.11 – 1.81)
>20,000	1.25 (0.57 – 2.71)	2.63 (0.73 – 35.33)
Household head education:		
No education	REF	REF
Primary school	0.97 (0.39 – 2.33)	1.10 (0.42 – 2.88)
High school	0.77 (0.37 – 1.60)	0.75 (0.16 – 1.91)
Higher	0.62 (0.26 – 1.49)	0.62 (0.07 – 1.96)
Electricity in home:		

No	REF	REF
Yes	1.46 (0.46 – 4.60)	1.93 (0.43 – 16.10)
Own home:		
No	REF	REF
Yes	0.25 (0.07 – 0.80)	0.06 (0.00 – 0.81)
Own land away from home:		
No	REF	REF
Yes	1.10 (0.56 – 2.12)	0.74 (0.34 – 1.62)
Mosquito control:		
No	REF	REF
Yes	0.67 (0.25 – 1.64)	0.44 (0.06 – 1.46)
Community level		
<i>A. aegypti</i> captured:		
No	REF	REF
Yes	5.52 (0.60 – 34.91)	3.52 (0.01 – 48.07)
<i>A. albopictus</i> captured:		
No	REF	REF
Yes	0.59 (0.08 – 6.29)	0.79 (0.09 – 15.79)
Population density (log scale):	1.22 (0.63 – 2.51)	0.48 (0.05 – 1.36)

492

493

494 **Supplementary figures**


495

496

497 **Figure S1. Histogram of the ratios between fluorescence intensity to CHIKV and the control**

498 **SNAP-tag protein with the cutoff point of 5.5 marked (dashed line). Samples to the left of the dashed**

499 **line are considered seronegative, and those to the right seropositive.**



500 **Figure S2.**

501

502

503

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520


521

522

523

524

525




526 **Figure S2: Difference in multivariable coefficient estimates.** Run using logistic regression with a
527 Matérn spatial correlation structure, random community intercept and a random household intercept
528 (Model 1), a Matérn spatial correlation structure and random household intercept only (Model 2) a
529 Matérn spatial correlation structure and random community intercept only (Model 3), a Matérn spatial

530 correlation structure only (Model 4), and random household and community intercepts only (Model
531 5).


532

533 **Figure S3.**

Aedes aegypti Status



Aedes albopictus Status



534

535

536 **Figure S3: Presence of *A. aegypti* and *A. albopictus* in communities.** The black triangles represent
537 the three main cities in Bangladesh.

538

539

540

541

542

543

544 **Table S1**

Model	WAIC
1 (Spatial correlation structure, community intercept and household intercept)	2190.89
2 (Spatial correlation structure and random household intercept)	3597.03
3 (Spatial correlation structure and random community intercept)	2306.11
4 (Spatial correlation structure)	3771.10
5 (Community and household random intercepts)	496.22

545

546 **Table S1: Model comparison**

547 **Table S2**

548

Multivariable	
Individual level	Adjusted odds ratio (95% confidence interval)
Age group (years):	
<5	0.00 (0.00 – 0.0001)
5-10	1.06 (0.38 – 2.96)
11-20	REF
21-30	0.84 (0.35 – 2.00)
31-40	0.83 (0.32 – 2.17)
41-50	1.29 (0.52 – 3.23)
51-60	2.00 (0.78 – 5.13)
>60	0.88 (0.29 – 2.73)
Sex:	
Female	REF
Male	0.58 (0.33 – 1.02)
Dengue Status:	
Seronegative	REF
Seropositive	1.75 (0.94 – 3.25)
Last time left community:	
<180 days	REF
>180 days	0.83 (0.44 – 1.55)
Household level	
Household income (Taka):	
<10,000	REF
10,000 – 20,000	0.84 (0.38 – 1.85)
>20,000	1.51 (0.59 – 3.87)
Household head education:	
No education	REF
Primary school	1.01 (0.39 – 2.61)
High school	0.79 (0.35 – 1.80)
Higher	0.70 (0.27 – 1.82)
Electricity in home:	
No	REF
Yes	1.21 (0.33 – 4.48)
Own home:	
No	REF

Yes	0.30 (0.07 – 1.19)
Own land away from home:	
No	REF
Yes	1.07 (0.50 – 2.27)
Mosquito control:	
No	REF
Yes	0.60 (0.22 – 1.57)
Community level	
<i>A. aegypti</i> captured:	
No	REF
Yes	0.47 (0.08 – 2.61)
<i>A. albopictus</i> captured:	
No	REF
Yes	2.51 (0.44 – 14.8)
Population density (log scale):	0.89 (0.46 – 1.68)

549 **Table S2: Results of logistic regression performed using data from the 16 communities with at**
550 **least one seropositive individual.**

551 **Table S3**

552

	Univariate	Multivariable
Individual level	Odds ratio (95% confidence interval)	Adjusted odds ratio (95% confidence interval)
Age group (years):		
<5	0.00 (0.00 - 4.11e7)	0.00 (0.00 - 6.42e6)
5-10	1.06 (0.39 - 3.11)	1.10 (0.39 - 3.10)
11-20	REF	REF
21-30	1.04 (0.45 - 2.56)	0.80 (0.33 - 1.94)
31-40	0.99 (0.38 - 2.74)	0.82 (0.29 - 2.21)
41-50	1.42 (0.57 - 3.78)	1.35 (0.53 - 3.46)
51-60	2.05 (0.83 - 5.36)	2.09 (0.76 - 6.88)
>60	0.98 (0.32 - 3.23)	0.90 (0.29 - 2.83)
Sex:		
Female	REF	REF
Male	0.74 (0.42 - 1.49)	0.55 (0.25 - 1.03)
Dengue Status:		
Seronegative	REF	REF
Seropositive	1.75 (0.89 - 3.24)	2.08 (1.01 - 6.52)
Last time left community:		
δ180 days	REF	REF
>180 days	1.18 (0.56 - 2.71)	0.75 (0.39 - 1.42)
Household level		
Household income (Taka):		
<10,000	REF	REF
10,000 - 20,000	0.73 (0.37 - 1.46)	0.82 (0.34 - 1.87)
>20,000	1.29 (0.59 - 2.81)	1.79 (0.68 - 4.82)
Household head education:		
No education	REF	REF
Primary school	0.96 (0.41 - 2.27)	1.07 (0.41 - 2.84)
High school	0.76 (0.37 - 1.56)	0.83 (0.36 - 1.90)
Higher	0.63 (0.26 - 1.47)	0.70 (0.25 - 1.91)
Electricity in home:		
No	REF	REF
Yes	1.28 (0.33 - 4.98)	1.31 (0.33 - 5.38)

Own home:		
No	REF	REF
Yes	0.27 (0.06 – 0.96)	0.23 (0.04 - 1.00)
Own land away from home:		
No	REF	REF
Yes	1.20 (0.63 – 2.30)	0.93 (0.42 - 2.18)
Mosquito control:		
No	REF	REF
Yes	0.60 (0.22 – 1.51)	0.59 (0.22 - 1.52)
Community level		
<i>A. aegypti</i> captured:		
No	REF	REF
Yes	4.14 (0.46 – 39.24)	5.29 (0.26 - 215.30)
<i>A. albopictus</i> captured:		
No	REF	REF
Yes	1.76 (0.31 – 11.15)	2.27 (0.16 - 30.23)
Population density (log scale):	0.62 (0.00 – 2.41)	1.05 (0.39 - 2.68)

553 **Table S3: Results of univariate and multivariable regression with a spatial field, random**
554 **community intercept and a random household intercept.**
555

556

557

558

559

560

561

562

563

564

565

566

567

568

569